According to a recent report by BioCentury, there have been nearly 40 start-ups engaging in build-to-buy deals since 2013. The build-to-buy model can be helpful to mitigate the inherent risk that comes along with new scientific discoveries and provide a solid exit strategy for early stage companies. By working in conjunction with a venture partner or negotiating a direct deal with pharma, our panel of experienced build-to-buy dealmakers from Cooley, PvP Biologics, Tempest Therapeutics and academia will share how this model has generated success for venture capitalists, founders and stakeholders.
Ability Level: All
Session ID: 21103